A Phase 1, single center, open label, randomized, parallel group, PK study of mavacamten with or without verapamil in healthy subjects.
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Mavacamten (Primary) ; Verapamil
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 07 Nov 2022 New trial record
- 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting